Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679367 · ClinicalTrials.gov registry record · Phase 2
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
A Phase 2 study, sponsored by Boston Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00679367 is a Phase 2 study that has completed, run by Boston Medical Center. The registered enrollment target is 16 participants.
The verdict
NCT00679367, a Phase 2 study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of abnormal plasma cells, either by killing the cells or by stopping them from dividing. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop the abnormal plasma cells from growing. Giving melphalan together with lenalidomide and dexamethasone may be an effective treatment for primary systemic amyloidosis. PURPOSE: This phase II trial is studying the side effects and how well giving melphalan together with lenalidomide and dexamethasone works in treating patients with primary systemic amyloidosis.
Interventions
- DRUG dexamethasone
- DRUG lenalidomide
- DRUG melphalan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-05 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00679367
The ClinicalTrials.gov registry entry for NCT00679367 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which dexamethasone is the first listed.
NCT00679367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00679367 about?
NCT00679367 is a clinical study titled "Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis". RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of abnormal plasma cells, either by killing the cells or by stopping them from dividing. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways...
What is the current status of trial NCT00679367?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2008-05. Estimated completion is 2015-05.
What interventions are being tested in trial NCT00679367?
The interventions under investigation include: dexamethasone (DRUG), lenalidomide (DRUG), melphalan (DRUG).
Who is sponsoring clinical trial NCT00679367?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.